Bayesian decomposition analysis of bacterial phylogenomic profiles

Ghislain Bidaut, Karsten Suhre, Jean Michel Claverie, Michael F. Ochs

Research output: Contribution to journalArticle

Abstract

Background: The past two decades have seen the appearance of new infectious diseases and the reemergence of old diseases previously thought to be under control. At the same time, the effectiveness of the existing antibacterial is is rapidly decreasing due to the spread of multidrug-resistant pathogens. Aim: The aim of this study was to the identify candidate molecular targets (e.g. enzymes) within essential metabolic pathways specific to a significant subset of bacterial pathogens as the first step in the rational design of new antibacterial drugs. Methods: We constructed a dataset of phylogenomic profiles (vectors that encode the similarity, measured by BLAST scores, of a gene across many species) for a series of 31 pathogenic bacteria of interest with 1073 genes taken from the reference organisms Escherichia coli and Mycobacterium tuberculosis. We applied Bayesian Decomposition, a matrix decomposition algorithm, to identify functional metabolic units comprising overlapping sets of genes in this dataset. Results: Although no information on phylogeny was provided to the system, Bayesian Decomposition retrieved the known bacteria phylogenic relationships on the basis of the proteins necessary for survival. In addition, a set of genes required by all bacteria was identified, as well as components and enzymes specific to subsets of bacteria. Conclusion: The use of phylogenomic profiles and Bayesian Decomposition provide important insights for the design of new antibacterial therapeutics.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalAmerican journal of pharmacogenomics : genomics-related research in drug development and clinical practice
Volume5
Issue number1
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Bayes Theorem
Bacteria
Overlapping Genes
Genes
Enzymes
Phylogeny
Metabolic Networks and Pathways
Mycobacterium tuberculosis
Communicable Diseases
Escherichia coli
Pharmaceutical Preparations
Proteins
Datasets
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Bayesian decomposition analysis of bacterial phylogenomic profiles. / Bidaut, Ghislain; Suhre, Karsten; Claverie, Jean Michel; Ochs, Michael F.

In: American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, Vol. 5, No. 1, 2005, p. 63-70.

Research output: Contribution to journalArticle

Bidaut, Ghislain ; Suhre, Karsten ; Claverie, Jean Michel ; Ochs, Michael F. / Bayesian decomposition analysis of bacterial phylogenomic profiles. In: American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2005 ; Vol. 5, No. 1. pp. 63-70.
@article{49bb29f1ce244315a234446a8d35beb9,
title = "Bayesian decomposition analysis of bacterial phylogenomic profiles",
abstract = "Background: The past two decades have seen the appearance of new infectious diseases and the reemergence of old diseases previously thought to be under control. At the same time, the effectiveness of the existing antibacterial is is rapidly decreasing due to the spread of multidrug-resistant pathogens. Aim: The aim of this study was to the identify candidate molecular targets (e.g. enzymes) within essential metabolic pathways specific to a significant subset of bacterial pathogens as the first step in the rational design of new antibacterial drugs. Methods: We constructed a dataset of phylogenomic profiles (vectors that encode the similarity, measured by BLAST scores, of a gene across many species) for a series of 31 pathogenic bacteria of interest with 1073 genes taken from the reference organisms Escherichia coli and Mycobacterium tuberculosis. We applied Bayesian Decomposition, a matrix decomposition algorithm, to identify functional metabolic units comprising overlapping sets of genes in this dataset. Results: Although no information on phylogeny was provided to the system, Bayesian Decomposition retrieved the known bacteria phylogenic relationships on the basis of the proteins necessary for survival. In addition, a set of genes required by all bacteria was identified, as well as components and enzymes specific to subsets of bacteria. Conclusion: The use of phylogenomic profiles and Bayesian Decomposition provide important insights for the design of new antibacterial therapeutics.",
author = "Ghislain Bidaut and Karsten Suhre and Claverie, {Jean Michel} and Ochs, {Michael F.}",
year = "2005",
doi = "10.2165/00129785-200505010-00006",
language = "English (US)",
volume = "5",
pages = "63--70",
journal = "American Journal of PharmacoGenomics",
issn = "1175-2203",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Bayesian decomposition analysis of bacterial phylogenomic profiles

AU - Bidaut, Ghislain

AU - Suhre, Karsten

AU - Claverie, Jean Michel

AU - Ochs, Michael F.

PY - 2005

Y1 - 2005

N2 - Background: The past two decades have seen the appearance of new infectious diseases and the reemergence of old diseases previously thought to be under control. At the same time, the effectiveness of the existing antibacterial is is rapidly decreasing due to the spread of multidrug-resistant pathogens. Aim: The aim of this study was to the identify candidate molecular targets (e.g. enzymes) within essential metabolic pathways specific to a significant subset of bacterial pathogens as the first step in the rational design of new antibacterial drugs. Methods: We constructed a dataset of phylogenomic profiles (vectors that encode the similarity, measured by BLAST scores, of a gene across many species) for a series of 31 pathogenic bacteria of interest with 1073 genes taken from the reference organisms Escherichia coli and Mycobacterium tuberculosis. We applied Bayesian Decomposition, a matrix decomposition algorithm, to identify functional metabolic units comprising overlapping sets of genes in this dataset. Results: Although no information on phylogeny was provided to the system, Bayesian Decomposition retrieved the known bacteria phylogenic relationships on the basis of the proteins necessary for survival. In addition, a set of genes required by all bacteria was identified, as well as components and enzymes specific to subsets of bacteria. Conclusion: The use of phylogenomic profiles and Bayesian Decomposition provide important insights for the design of new antibacterial therapeutics.

AB - Background: The past two decades have seen the appearance of new infectious diseases and the reemergence of old diseases previously thought to be under control. At the same time, the effectiveness of the existing antibacterial is is rapidly decreasing due to the spread of multidrug-resistant pathogens. Aim: The aim of this study was to the identify candidate molecular targets (e.g. enzymes) within essential metabolic pathways specific to a significant subset of bacterial pathogens as the first step in the rational design of new antibacterial drugs. Methods: We constructed a dataset of phylogenomic profiles (vectors that encode the similarity, measured by BLAST scores, of a gene across many species) for a series of 31 pathogenic bacteria of interest with 1073 genes taken from the reference organisms Escherichia coli and Mycobacterium tuberculosis. We applied Bayesian Decomposition, a matrix decomposition algorithm, to identify functional metabolic units comprising overlapping sets of genes in this dataset. Results: Although no information on phylogeny was provided to the system, Bayesian Decomposition retrieved the known bacteria phylogenic relationships on the basis of the proteins necessary for survival. In addition, a set of genes required by all bacteria was identified, as well as components and enzymes specific to subsets of bacteria. Conclusion: The use of phylogenomic profiles and Bayesian Decomposition provide important insights for the design of new antibacterial therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=20444399200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444399200&partnerID=8YFLogxK

U2 - 10.2165/00129785-200505010-00006

DO - 10.2165/00129785-200505010-00006

M3 - Article

VL - 5

SP - 63

EP - 70

JO - American Journal of PharmacoGenomics

JF - American Journal of PharmacoGenomics

SN - 1175-2203

IS - 1

ER -